Deutsche Bank
NRIX icon

Deutsche Bank’s Nurix Therapeutics NRIX Stock Holding History

Deutsche Bank’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$35.6M Sell
2,295,024
-191,768
-8% -$3.18M 0.01% 717
2025
Q4 		$47.2M Buy
2,486,792
+1,047,933
+73% +$15.1M 0.02% 650
2025
Q3 		$13.3M Buy
1,438,859
+1,069,981
+290% +$11.1M ﹤0.01% 969
2025
Q2 		$4.2M Sell
368,878
-11,270
-3% -$122K ﹤0.01% 1318
2025
Q1 		$4.52M Sell
380,148
-151,049
-28% -$2.53M ﹤0.01% 1291
2024
Q4 		$10M Sell
531,197
-323,485
-38% -$7.41M ﹤0.01% 1025
2024
Q3 		$19.2M Sell
854,682
-193,712
-18% -$4.39M 0.01% 843
2024
Q2 		$21.9M Sell
1,048,394
-450,974
-30% -$7.02M 0.01% 793
2024
Q1 		$22M Buy
1,499,368
+995,163
+197% +$10.7M 0.01% 785
2023
Q4 		$5.2M Buy
504,205
+484,610
+2,473% +$3.32M ﹤0.01% 1239
2023
Q3 		$154K Buy
19,595
+3,841
+24% +$35.1K ﹤0.01% 2938
2023
Q2 		$157K Sell
15,754
-12,659
-45% -$129K ﹤0.01% 3027
2023
Q1 		$252K Buy
28,413
+8,667
+44% +$90.3K ﹤0.01% 2896
2022
Q4 		$217K Buy
19,746
+310
+2% +$3.74K ﹤0.01% 2940
2022
Q3 		$253K Sell
19,436
-1,527
-7% -$24.2K ﹤0.01% 2804
2022
Q2 		$266K Buy
20,963
+3,011
+17% +$34.1K ﹤0.01% 2999
2022
Q1 		$252K Sell
17,952
-2,018
-10% -$35.8K ﹤0.01% 3128
2021
Q4 		$578K Buy
19,970
+677
+4% +$20.5K ﹤0.01% 2743
2021
Q3 		$578K Sell
19,293
-582
-3% -$18K ﹤0.01% 2929
2021
Q2 		$527K Buy
19,875
+4,130
+26% +$121K ﹤0.01% 3188
2021
Q1 		$490K Buy
15,745
+2,709
+21% +$102K ﹤0.01% 3115
2020
Q4 		$429K Buy
13,036
+7,105
+120% +$235K ﹤0.01% 3009
2020
Q3 		$207K Buy
+5,931
New +$149K ﹤0.01% 3193

Other funds holding NRIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Deutsche Bank's NRIX Position: Q1 2026 in Review

Deutsche Bank reduced its Nurix Therapeutics (NRIX) stake by 7.7% in Q1 2026, selling an estimated $3.18M and leaving 2,295,024 shares worth $35.6M. The position accounts for 0.01% of the portfolio, ranked #717.

Deutsche Bank first reported a position in NRIX in Q3 2020 and has held it in 23 quarters since. The position peaked at $47.2M in Q4 2025. 195 funds tracked by Wall St. Rank hold NRIX as of Q1 2026.

  • Deutsche Bank held 2,295,024 shares of Nurix Therapeutics worth $35.6M as of Q1 2026.
  • Deutsche Bank sold 191,768 Nurix Therapeutics shares in Q1 2026, an estimated $3.18M.
  • Nurix Therapeutics made up 0.01% of Deutsche Bank's portfolio in Q1 2026, its #717 holding.
  • Deutsche Bank first reported a position in Nurix Therapeutics in Q3 2020 and has held it in 23 quarters since.
  • Deutsche Bank's Nurix Therapeutics position peaked at $47.2M in Q4 2025.
  • 195 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2026.

Based on Deutsche Bank's 13F filing for Q1 2026, filed 6 May 2026.